Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: NLSPW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -80% | Avg. Invested days 10 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1687887 |
Shares Outstanding - | Shares Floating 1687887 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare and complex central nervous system disorders.
Core Business Areas
- Quilience (mazindol ER): NLS Pharmaceutics' primary focus is on the development and commercialization of Quilience, an extended-release formulation of mazindol. It is being developed for the treatment of narcolepsy. Other indications being explored include ADHD.
Leadership and Structure
The leadership team includes key executives in areas such as clinical development, regulatory affairs, and finance. Organizational structure is typical of a small biopharmaceutical company.
Top Products and Market Share
Key Offerings
- Quilience (mazindol ER): Quilience is an extended-release formulation of mazindol being developed for narcolepsy and ADHD. Market share data is currently unavailable as it is not yet approved for sale. Competitors include stimulant and non-stimulant medications from companies like Jazz Pharmaceuticals and Takeda Pharmaceutical.
Market Dynamics
Industry Overview
The CNS disorder market is characterized by significant unmet needs and growing patient populations, driving demand for novel therapies.
Positioning
NLS Pharmaceutics aims to address unmet needs in narcolepsy and ADHD with Quilience, offering a potentially differentiated treatment option.
Total Addressable Market (TAM)
The TAM for narcolepsy and ADHD is substantial, estimated in the billions of dollars globally. NLS Pharmaceutics' positioning hinges on successful clinical trials and market access for Quilience.
Upturn SWOT Analysis
Strengths
- Novel formulation of mazindol (Quilience)
- Focus on unmet needs in CNS disorders
- Experienced management team
Weaknesses
- Limited financial resources
- Single product pipeline (Quilience)
- Regulatory approval risks
Opportunities
- Successful clinical trial outcomes
- Strategic partnerships
- Expansion into new indications
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JAZZ
- TAK
Competitive Landscape
NLS Pharmaceutics faces intense competition from established pharmaceutical companies with marketed products for narcolepsy and ADHD. Its advantage depends on demonstrating superior efficacy and safety with Quilience.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by clinical development progress.
Future Projections: Future growth depends on successful clinical trials, regulatory approval, and commercialization of Quilience.
Recent Initiatives: Recent initiatives include advancing clinical trials for Quilience and seeking strategic partnerships.
Summary
NLS Pharmaceutics is a small biopharmaceutical company focused on developing Quilience for CNS disorders. Success hinges on clinical trial outcomes and regulatory approval. The company faces significant competition and financial risks, but it has the potential to address unmet needs in the narcolepsy and ADHD markets. They need to look out for any adverse regulatory decisions on products in their pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in pharmaceutical companies is inherently risky, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.